A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, association, enzyme, gene, PTEN, surveillance | 4 Comments »
Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: BRCA1/2, gene, hereditary, PSA, risk, status, velocity | 1 Comment »
A new paper by an international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aggressive, expression, EZH2, gene, indolent, risk, TOP2A | 1 Comment »
Within the past few hours, the US Food and Drug Administration (FDA) has approved the very first form of chimeric antigen receptor (CAR) T-cell therapy for the treatment of cancer — and this is also the first true form of gene therapy to be made available here in the US. … READ MORE …
Filed under: Uncategorized | Tagged: CAR-T, CTL019, gene, Kymriah, therapy, tisagenlecleucel | 2 Comments »
A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: gene, grade, growth, Height, risk | 1 Comment »
A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, gene, receptor, resistance, test | 4 Comments »
According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, aggressive, gene, HSD3BI, LESS, responsive | 2 Comments »
